- Home
- FIVE vs BMRN Comparison
FIVE vs BMRN Comparison
Compare FIVE & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIVE | BMRN |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 10.0B |
| IPO Year | 2012 | 1999 |
Fundamental Metrics
Financial Performance| Metric | FIVE | BMRN |
|---|---|---|
| Price | $195.39 | $59.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 19 |
| Target Price | ★ $174.11 | $89.74 |
| AVG Volume (30 Days) | 1.2M | ★ 2.9M |
| Earning Date | 12-03-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.58 | ★ 59.53 |
| EPS | ★ 5.56 | 2.68 |
| Revenue | ★ $4,426,552,000.00 | $3,094,001,000.00 |
| Revenue This Year | $22.15 | $13.35 |
| Revenue Next Year | $9.84 | $9.06 |
| P/E Ratio | $35.16 | ★ $21.99 |
| Revenue Growth | ★ 15.78 | 12.39 |
| 52 Week Low | $52.38 | $50.76 |
| 52 Week High | $204.67 | $73.51 |
Technical Indicators
Market Signals| Indicator | FIVE | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 66.95 | 55.71 |
| Support Level | $185.93 | $58.38 |
| Resistance Level | $204.67 | $61.88 |
| Average True Range (ATR) | 5.16 | 2.08 |
| MACD | 0.11 | 0.05 |
| Stochastic Oscillator | 62.30 | 49.68 |
Price Performance
Historical ComparisonAbout FIVE Five Below Inc.
Five Below Inc is a specialty value retailer offering merchandise targeted at the tween and teen demographic. The Company's edited assortment of products includes select brands and licensed merchandise. It derives revenue from sales of the Company's merchandise to customers.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.